Table 1.
Summary of clinical trials focusing on proteolysis-targeting chimeras (PROTACs) described in this review.
| # | Drug | Route | E3 Ligand | Target Protein Ligand | Disease | Sponsor | Phase | Study Start Date | Study Completion Date | ClinicalTrials.gov Identifier (accessed on 15 January 2023) |
Status |
|---|---|---|---|---|---|---|---|---|---|---|---|
| (i) | AC682 | Oral | CRBN | ER | Cancer | Accutar Biotechnology, Inc. | Phase 1 | 12 November 2021 | September 2023 | NCT05080842 | Recruiting |
| (ii) | CC-94676 | Oral | CRBN | Non-steroidal AR | Cancer | Celgene | Phase 1 | 22 June 2020 | 27 February 2025 | NCT04428788 | Recruiting |
| (iii) | DT2216 | Intravenous | VHL | Bcl-XL | Cancer | Dialectic Therapeutics, Inc. | Phase 1 | 25 August 2021 | 15 April 2023 | NCT04886622 | Recruiting |
| (iv) | FHD-609 | Intravenous | CRBN | BRD9 | Cancer | Foghorn Therapeutics, Inc. | Phase 1 | 17 August 2021 | 31 May 2025 | NCT04965753 | Recruiting |
| (v) | KT-474 | Oral | CRBN | IRAK4 | Cancer | Kymera Therapeutics, Inc. | Phase 1 | 23 February 2021 | 20 October 2022 | NCT04772885 | Completed |
| (vi) | KT-413 | Intravenous | CRBN | IRAK4 | Cancer | Kymera Therapeutics, Inc. | Phase 1 | 13 June 2022 | May 2025 | NCT05233033 | Recruiting |
| (vii) | NX-2127 | Oral | CRBN | BTK | Cancer | Nurix Therapeutics, Inc. | Phase 1 | 5 May 2021 | November 2023 | NCT04830137 | Recruiting |
| (viii) | NX-5948 | Oral | CRBN | BTK | Cancer | Nurix Therapeutics, Inc. | Phase 1 | 13 April 2022 | May 2024 | NCT05131022 | Recruiting |
| (ix) | ARV-110 | Oral | CRBN | Non-steroidal AR | Cancer | Arvinas Androgen Receptor, Inc. | Phase 1 Phase 2 |
1 March 2019 | 31 October 2023 | NCT03888612 | Recruiting |
| (x) | ARV-471 | Oral | CRBN | ER ligand | Cancer | Arvinas Estrogen Receptor, Inc. | Phase 1 Phase 2 |
5 August 2019 | June 2023 | NCT04072952 | Recruiting |
| (xi) | ARV-766 | Oral | VHL | BRD4 | Cancer | Arvinas Androgen Receptor, Inc. | Phase 1 Phase 2 |
2 September 2021 | 27 June 2025 | NCT05067140 | Recruiting |